相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
D. W. Kufe
ONCOGENE (2013)
Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
Amy D. Guertin et al.
CANCER CELL INTERNATIONAL (2012)
Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Maurizio Scaltriti et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Dependence on the MUC1-C Oncoprotein in Non-Small Cell Lung Cancer Cells
Deepak Raina et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
Maurizio Scaltriti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance
Si Tuen Lee-Hoeflich et al.
CANCER DISCOVERY (2011)
Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
Xiaoping Huang et al.
CANCER RESEARCH (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
A novel interaction between HER2/neu and cyclin E in breast cancer
E. A. Mittendorf et al.
ONCOGENE (2010)
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells
Shawn P. Fessler et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
Deepak Raina et al.
CANCER RESEARCH (2009)
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2009)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M. Scaltriti et al.
ONCOGENE (2009)
Mucins in cancer: function, prognosis and therapy
Donald W. Kufe
NATURE REVIEWS CANCER (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
Si Tuen Lee-Hoeflich et al.
CANCER RESEARCH (2008)
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
David L. Shattuck et al.
CANCER RESEARCH (2008)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62
Yumei Leng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling
Rita Nahta et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2005)
MUC1 oncoprotein blocks glycogen synthase kinase 3β-mediated phosphorylation and degradation of β-catenin
L Huang et al.
CANCER RESEARCH (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
P27Kip1 stabilization and G1 arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box Protein/Skp2 ubiquitin ligase
PF Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Human DF3/MUC1 carcinoma-associated protein functions as an oncogene
YQ Li et al.
ONCOGENE (2003)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Segregation of receptor and ligand regulates activation of epithelial growth factor receptor
PD Vermeer et al.
NATURE (2003)
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer
G Viglietto et al.
NATURE MEDICINE (2002)
PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization
I Shin et al.
NATURE MEDICINE (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
